GlassScriptPhysician profile
Terry Vuong
NPI 1700317195
$9,394.16
in general payments reported to CMS, 2019-2025
39 companies · $2,548 in 2025
The $2,548 reported for 2025 was more than what 83% of Obesity Medicine (Family Medicine) providers received nationally (typical 2025 total: $183).
See the full distribution for Obesity Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.86 · 2020: $27.16 · 2022: $1,189 · 2023: $2,086 · 2024: $3,531 · 2025: $2,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,164.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,526.89 | 2022-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,225.17 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $600.84 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $557.44 | 2022-2025 | Quviviq, Quviviq |
| Lilly USA, LLC | $548.91 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $524.97 | 2020-2025 | Evenity, Prolia, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $515.68 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $496.37 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Merck Sharp & Dohme LLC | $481.97 | 2020-2025 | Verquvo, Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $381.75 | 2022-2025 | Veozah |
| Exact Sciences Corporation | $373.96 | 2023-2025 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $357.67 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $247.13 | 2022-2025 | Caplyta |
| Axsome Therapeutics, INC. | $243.74 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $182.37 | 2025 | Spravato |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.74 | 2022-2024 | Ofev |
| Alnylam Pharmaceuticals INC. | $122.83 | 2023 | Amvuttra |
| Pfizer INC. | $119.16 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $93.41 | 2024 | |
| Viiv Healthcare Company | $90.23 | 2024-2025 | Apretude |
| Amneal Pharmaceuticals LLC | $69.60 | 2024-2025 | Unithroid |
| Eisai INC. | $46.98 | 2022-2025 | |
| Inspire Medical Systems, INC. | $46.82 | 2024 | Inspire |
| Abbott Laboratories | $45.68 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Renalytix Ai, INC. | $44.68 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Vivus LLC | $34.72 | 2023-2024 | Qsymia |
| Corcept Therapeutics | $34.00 | 2023 | Korlym |
| Esperion Therapeutics, INC. | $30.81 | 2022-2023 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $25.87 | 2022 | |
| Phathom Pharmaceuticals, INC. | $25.04 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $21.56 | 2025 | Gemtesa |
| Dynavax Technologies Corporation | $21.33 | 2024 | Heplisav-B |
| Regeneron Healthcare Solutions, INC. | $21.27 | 2025 | Evkeeza |
| Philips North America LLC | $21.01 | 2024 | (Ck7) Extended Holter |
| Bausch Health US, LLC | $20.84 | 2024 | Aplenzin |
| Dexcom, INC. | $19.97 | 2023 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $18.67 | 2023 | Gralise, Loreev Xr |
| Kowa Pharmaceuticals America, INC. | $17.22 | 2022 | |
| Genentech USA, INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Vuong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.